Safety and Efficacy of Emixustat in Stargardt Disease
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if emixustat hydrochloride reduces the rate of
progression of macular atrophy compared to placebo in subjects with Stargardt disease.
Funding Source -- FDA OOPD